U.S. markets open in 1 hour 34 minutes

Navidea Biopharmaceuticals, Inc. (NAVB)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
1.9600-0.0200 (-1.01%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close1.9800
Open1.9900
Bid1.9000 x 3000
Ask0.0000 x 1300
Day's Range1.9161 - 2.0400
52 Week Range1.4600 - 5.3600
Volume110,735
Avg. Volume199,209
Market Cap56.89M
Beta (5Y Monthly)1.77
PE Ratio (TTM)N/A
EPS (TTM)-0.4520
Earnings DateAug 11, 2021 - Aug 16, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Here is What Hedge Funds Think About Navidea Biopharmaceuticals Inc (NAVB)
    Insider Monkey

    Here is What Hedge Funds Think About Navidea Biopharmaceuticals Inc (NAVB)

    The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 866 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]

  • Navidea Biopharmaceuticals Announces Issuance of U.S. Patent for Diagnosis and Treatment of Viral Infections
    Business Wire

    Navidea Biopharmaceuticals Announces Issuance of U.S. Patent for Diagnosis and Treatment of Viral Infections

    Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that the U.S. Patent and Trademark Office ("USPTO") issued to Navidea U.S. patent 11,007,272, entitled "Compounds and Methods for Diagnosis and Treatment of Viral Infections," with protection to October 7, 2037.

  • Navidea Biopharmaceuticals Reports First Quarter 2021 Financial Results
    Business Wire

    Navidea Biopharmaceuticals Reports First Quarter 2021 Financial Results

    Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the first quarter for the period ended March 31, 2021.